Y-mAbs Therapeutics, Inc.
YMAB · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.39 | 0.48 | 2.07 | 0.88 |
| FCF Yield | 0.81% | -3.52% | -0.53% | -1.82% |
| EV / EBITDA | -25.91 | -21.41 | -48.84 | -61.54 |
| Quality | ||||
| ROIC | -5.93% | -6.96% | -5.52% | -9.35% |
| Gross Margin | 86.37% | 85.64% | 70.40% | 87.82% |
| Cash Conversion Ratio | -0.51 | 1.33 | 0.28 | 1.52 |
| Growth | ||||
| Revenue 3-Year CAGR | 0.16% | 5.72% | 10.34% | 24.88% |
| Free Cash Flow Growth | 123.46% | -276.36% | 82.47% | -3,678.86% |
| Safety | ||||
| Net Debt / EBITDA | 10.56 | 9.13 | 11.38 | 7.94 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.27 | 0.38 | 1.09 | 0.24 |
| Cash Conversion Cycle | 145.18 | 177.38 | 73.21 | 164.31 |